Blinatumomab (Blincyto) — CPB 0891 | AETNA Coverage Update

Aetna modified CPB 0891 for blinatumomab (Blincyto), effective November 1, 2025. Here's what changes for billing teams.

Aetna, a CVS Health company, updated its blinatumomab coverage policy under CPB 0891 Aetna system, with an effective date of November 1, 2025. The update defines medical necessity criteria across three distinct treatment settings for CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL). If your team bills J9039 for blinatumomab injections alongside CPT 96413–96417 for chemotherapy administration, this coverage policy directly shapes what you submit and what gets paid.

Quick-Reference Table

Aetna Blinatumomab Coverage Criteria and Medical Necessity Requirements 2025

The Aetna blinatumomab coverage policy under CPB 0891 covers blinatumomab for CD19-positive B-cell precursor ALL under three medical necessity pathways. You need to meet at least one. Missing documentation on any of these pathways is a fast path to claim denial.

Pathway 1: Induction therapy for Philadelphia chromosome-positive disease. Blinatumomab must be used in combination with a tyrosine kinase inhibitor (TKI). Aetna's policy names specific TKIs: bosutinib, dasatinib, imatinib, nilotinib, and ponatinib. If your patient is on a TKI not on that list, flag it before billing J9039.

Pathway 2: Consolidation or maintenance therapy. This is a broad category. The policy does not specify a line of therapy or remission status here. But your documentation still needs to confirm the treatment setting — consolidation or maintenance — or you're leaving the claim open to a medical necessity challenge.

Pathway 3: Relapsed or refractory disease. This is the most common prior authorization scenario in practice. Your chart documentation should clearly support the relapsed or refractory designation before the claim goes out.

The policy applies to commercial medical plans only. For Aetna Medicare members, billing guidelines differ — check Aetna's Medicare Part B Step Therapy criteria separately.

Prior authorization is a near-certainty for J9039 given the drug's cost. Confirm prior auth requirements with Aetna for each patient before the first infusion cycle. A single missing auth can put five-figure reimbursement at risk.

Aetna Blinatumomab Exclusions and Non-Covered Indications

Aetna is direct here: all indications not listed in Section I of CPB 0891 are considered experimental, investigational, or unproven.

This matters for any off-label use. If a provider is using blinatumomab for a diagnosis outside CD19-positive B-cell precursor ALL — for example, T-cell malignancies or other hematologic cancers — Aetna will not cover it under this policy. Billing J9039 against those cases produces a denial. Period.

The real issue here is documentation specificity. "Acute lymphoblastic leukemia" on a claim is not enough. You need CD19-positive B-cell precursor ALL confirmed in the chart. Submitting ICD-10 C91.00, C91.01, or C91.02 without pathology or immunophenotyping support in the record creates audit exposure.

Coverage Indications at a Glance

Aetna Blinatumomab Billing Guidelines and Action Items 2025

CPT, HCPCS, and ICD-10 Codes for Blinatumomab Under CPB 0891

HCPCS Codes — Covered When Selection Criteria Are Met

CPT Codes — Related to Chemotherapy Administration

HCPCS Codes — Other Related Codes

Key ICD-10-CM Diagnosis Codes

One note on the ICD-10 coding here: the policy lists a broad range of malignant solid tumor codes. Your primary diagnosis for blinatumomab reimbursement should be in the C91.0x range. The broader malignancy codes reflect the full scope of the CPB document, not covered blinatumomab indications. Don't bill J9039 against a solid tumor ICD-10 and expect it to pass medical necessity review — it won't.